A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Safety and Tolerability of Oral PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis
Research Grant
Administered By
Ophthalmology
Awarded By
Pipeline Therapeutics, Inc
Start Date
January 27, 2022
End Date
January 31, 2024
Administered By
Ophthalmology
Awarded By
Pipeline Therapeutics, Inc
Start Date
January 27, 2022
End Date
January 31, 2024